Olanzapine efficacy in the treatment of cocaine abuse in methadone maintenance patients. Interaction with plasma levels;Eficacia del antipsicótico olanzapina en el tratamiento del abuso de cocaína en pacientes en mantenimiento con metadona. Interacción en los niveles plasmáticos

Actas Espanolas de Psiquiatria

Volumn 29, Issue 4, 2001, Pages 215-220

  Bano M D ^a   Mico J A ^b   Agujetas, M ^a   Lopez M L ^b   Guillen J L ^b  

^a Programa Municipal de Drogas   (Spain)

^b NONE

Author keywords

Cocaine; Methadone; Olanzapine; Pharmacokinetic interaction; Plasma levels

Indexed keywords

BENZODIAZEPINE DERIVATIVE; COCAINE; DRUG DERIVATIVE; METHADONE; NARCOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PIRENZEPINE;

ADULT; ARTICLE; BLOOD; COCAINE DEPENDENCE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG INTERACTION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MALE; METABOLISM; TREATMENT OUTCOME; URINE; WITHDRAWAL SYNDROME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COCAINE; COCAINE-RELATED DISORDERS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; METHADONE; NARCOTICS; PIRENZEPINE; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 0035408273     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Casas M, Duró P. Los programas de mantenimiento con antagonistas opiáceos desde la perspectiva de las neurociencias. Farmacéuticos 1999;227:55-8.
2. Kessler RC, McGonagle KA, Zhao S. Lifetime and 12-month prevalence of DSM III R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19.
3. Batki SL, Manfredi LB, Jacob P, Jones RT. Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecognine concentrations. J Clin Psychopharmacol 1993; 13:243-50.
4. Ochoa E. Cocaína y comorbilidad psiquiátrica. Actas Esp Psiquiatría 2000;28:40-52.
5. Halkas J, Crosby RD, Graves N. Double -blind carbamazepine enhacement in the treatment of cocaine abuse. Abstracts: Annual meeting of the American College of Neuropsychopharmacology 1992:231.
6. Kosten T. Diverse pharmacological agents for possible treatment of cocaine dependency. Presented at the Annual Meeting of the College on problems of Drug Dependence, Symposium VIII, Keystone, Colorado; 1992.
7. Gawin FH, Kleber HD. Cocaine abuse treatment-open pilot trial with desipramine and lithium carbonate. Arc Gen Psychiatry 1984;41:903-9.
8. Kleber HD, Gawin FH. Psychopharmacological trials in cocaine abuse treatment. Am J Drug Alcohol Abuse 1986;12:235-46.
9. Kosten TR, Rousanville BJ, Kleber HD. A 2.5 year follow up of cocaine use among opioid addicts. Arch Gen Psychiatry 1987;44:281-4.
10. Fischman MW, Foltin RW, Nestadt G, Pearlson GD. Effects of desipramine maintenance on cocaine self-administration by humans. J Pharmacol Exp Ther 1990;253:760-70.
11. Arndt IO, Dorozynsky L, Woody E, McLellan AT, O'Brien CP. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch Gen Psychiatry 1992;49:888-93.
12. Batki SL, Manfredi LB, Sorenson J, Jacob P, Dumontent R, Jones RT. Fluoxetine for cocaine abuse in methadone patients: preliminary findings. Proceedings of the Annual Meeting of the Committee on Problems for Drug Dependence, NIDA Research Monograph 105. Washington, DC: DHHS; 1991. p. 516-7.
13. Baño MD, Agujetas M, López ML, Tena T, Rodríguez A, Lora-Tamayo C, Guillén JL. Eficacia de la fluoxetina en el tratamiento de la adicción a cocaína en pacientes en mantenimiento con metadona y su interacción en los niveles plasmáticos. Actas Esp Psquiatr 1999;27:321-4.
14. Oliveto A, Kosten TR, Schottenfeld R, Falcioni J, Ziedonis D. Desipramine, Amantadine, or Fluoxetine in Buprenorphine-Maintained cocaine users. J Substance Abuse Treat 1995;12:423-8.
15. Covi L, Hess JM, Kreiter NA, Haertzen CA. Three models for the analysis of a fluoxetine placebo controlled treatment in cocaine dependence. Proceedings of the Annual Meeting of the College on Problems of Drug Dependence. NIDA Research Monograph 141. Washington, DC: DHHHS; 1994. p. 138.
16. Grabowsky J, Rhoades H, Elk R, Schmidt J, Davis C, Creson D, Kirby K. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled double-blind trials. J Clin Psychopharmacol 1995;15: 163-74.
17. Conley R, Kelly D, Gale E. Olanzapine response in treatment-refractory schizophrenic patients with a history of sustance abuse. Schizophr Res 1998;33: 95-101.
18. Batholoni G. Preferential effect of noncataleptic neuroleptics on mesolimbic dopaminergic function. Adv Biochem Pharmacol 1977;16:607-14.
19. Meil WM, Schechter MD. Olanzapine attenuates the reinforcing effects of cocaine. Eur J Pharmacol 1997;340:17-26.
20. Moreno Brea MR, Rojas Corrales O, Gibert-Rahola J, Micó JA. Interacciones medicamentosas de metadona con psicofármacos. Actas Esp Psiquiatr 1999;27: 103-10.
21. Wolff K, Hay A, Raistrick D, Calvert R. Steady-state pharmacokinetics of methadone in opioid addicts. Eur J Clin Pharmacol 1993;44:189-94.
22. Micó JA, Rojas MO, Moreno MR. Interacciones medicamentosas de la metadona. Farmacéuticos 1999; 227:50-4.
23. Roberts DCS, Loh EA, Vickers G. Self administration of cocaine on a progressive ratio schedules in rats: Dose-response relationship and effects of haloperidol pretreatment. Pharmacol 1989;97:535-8.
24. Wrighton SA, Ring BJ. Predicting drug interactions and pharmacokinetic variability with in vitro methods: The Olanzapine experience. Drug Metabolism Reviews 1999;31:15-28.
25. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: Pharmacokinetic and pharmacodynamic profile. Clinical Pharmacokinet 1999;37:177-93.
26. Guillén JL, López ML. Técnica analítica para la determinación de niveles plasmáticos de metadona. En: Cabrera J, Guillén JL, eds. La Huella de la Metadona. Niveles plasmáticos. Un instrumento clínico para mejorar tratamientos. Madrid: Delos; 1998. p. 457-72.
27. Smelson DA, Roy A, Roy M. Risperidone dimishes cue-elicited craving in withdrawn cocaine-dependent patients. Can J Psychiatry 1997;42:984.
28. Roy A, Roy M, Smelson DA. Risperidone, ERG, and cocaine craving. Am J Addict 1998;7:90.
29. th Annual Meeting of the American College of Neuropsychopharmacology, Waikoloa, Hawai, USA; 1997. p. 8-12.
30. Rubio G, Ponce G, Jiménez MA. Eficacia de risperidona en el manejo de problemas clinicos en toxicomanías. Trastornos Adictivos 2000;4(Supl 1):243-56.
31. Grabowsky J, Rhoades H, Silverman P, Schmitz JM, Stotts A, Creson D, Bailey R. Risperidone for the treatment of cocaine dependence: Randomized, double-blind trial. J Clin Psychopharmacol 2000;20:305-10.
32. Ring BJ, Binlkley SN, Vanderbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450, CYP2C9, CUP2C19, CYP2D6 y CYP3A. Br J Clin Pharmacol 1996;41:181-6.
33. Wines JD, Weiss RD. Opioid withdrawal during risperidone treatment. J Clin Psychopharmacol 1999; 19:265-7.
34. Iribarne C, Picart D, Dréano Y, Berthou F. In vitro interactions between fluoxetine and fluvoxamine and methadone or buprenorphine. Fundam Clin Pharmacol 1998;12:194-9.
35. Beauvirie P, Taburet AM, Desalles M-C, Furlan V, Touznau D. Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors. AIDS 1998;12-18:2310-1.
36. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13:957-62.
37. Heelon MW, Meade LB. Methadone withdrawal when starting an antirretroviral regimen including nevirapine. Pharmacotherapy 1999;19:471-2.
38. Baño MD, Agujetas M, López ML, Guillén JL. La nevirapina induce síntomas de abstinencia en pacientes en programa de mantenimiento con metadona con infección VIH. Rev Clin Esp 2000;200:12-4.